. Single chain antibodies fused to protein polymers are thermally-responsive. (a) Optical density was used to characterize the phase behavior of native scFv-A192 as a function of concentration.
The solution temperature was increased at a rate of 1 °C per minute and the bulk phase transition temperature was defined as the temperature where the steepest slope was recorded. (b) When compared to an ELP that lacks the scFv domain, A192, the scFv-A192 fusion reduced the transition temperature by ~ 15 °C. The transition temperatures for scFv-A192 and A192 were fit (dark line) to the following equation:
T t = -2.6 log 10 (Concentration) + 48.6. The dashed line indicates the 95% confidence interval around the prediction line.
3 Figure S2 . The hydrodynamic radius of nanoworms is stable below the bulk transition temperature.
Nanoparticles (blue) formed after renaturation of scFv-A192 are compared to A192 that lacks the scFv (red). Dynamic light scattering was obtained over a temperature gradient between 25 and 40 °C at 1 °C/min showed no significant change in particle size. The data plotted are the mean hydrodynamic radius and the error bars indicate the standard deviation of the population (nm).
Figure S3. Rituximab and nanoworms show minimal binding to CEM cells, which lack the CD20
receptor. CEM cells were incubated with 50 µg of rhodamine N-hydroxysuccinimide labeled protein in Dulbecco's Phosphate Buffered Saline (with 1% bovine serum albumin) for 15 mins and imaged using confocal laser scanning microscopy. The normalized intensity of rhodamine from the images was calculated using ImageJ (n=3) (a) CEM cells show minimal binding of Rituximab (RTXN) and nanoworms, which is consistent with a lack of CD20 expression. (b) Nanoworms show enhanced binding to CD20+ Raji cells compared to CD20-CEM cells (Unpaired student t-test, α=0.05 P=0.014). (c) Cell viability of Rituximab treated Raji, CEM and SU-DHL-7 cells was evaluated using a formazan based colorimetric assay, MTS. Rituximab showed a concentration dependent reduction in SU-DHL-7 cell viability with an IC 50 of 4.8 µM. Raji and CEM showed no reduction in viability on Rituximab treatment.
The data shown is the mean ± SD for each concentration (n=3).
5 Figure S4 . Unmodified A192 shows minimal binding or apoptotic signaling of CD20+ cells.
Rhodamine N-hydroxysuccinimide labeled A192 was incubated with Raji and SU-DHL-7 and imaged using confocal laser scanning microscopy. (a) A192 showed minimal binding to both CD20+ cell lines. implanted with the CD20+ Raji tumor cells on day zero. Tumor measurements were taken using calipers, and measurements were blinded to the treatment group throughout the duration of the study. These data include data from all of the individual mice evaluated in the study depicted in Fig. 6 of the main text.
Doses were administered on days indicated with major tick marks. The three treatment groups included:
(a) phosphate buffered saline; (b) Rituximab (1.7 mg/dose); and (c) nanoworms (2.5 mg/dose). Individual tumor growth profiles show minimal within group variability. Figure S6 . Nanoworm treatment is tolerated in animals. Athymic nude mice were implanted with the CD20+ Raji tumor cells on day zero. The body weights for mice treated with nanoworms (2.5 mg/dose), Rituximab (RTXN, 1.7 mg/dose), and phosphate buffered saline (PBS) were recorded throughout the duration of the study. Doses were administered on days indicated with major tick marks. These data points indicate the mean ± SD (n=5) from the same study depicted in the Fig. 6 of the main text. and tumor volumes for mice treated with nanoworms (2.5 mg/dose), Rituximab (1.7 mg/dose), and phosphate buffered saline (PBS) were recorded throughout the duration of the study. After the tumor volume endpoint of 1000 mm 3 was reached, the tissues were harvested, fixed and weighed. These data points indicate the mean ± SD (n=3) from the study depicted in the Fig. 6 of the main text.
